nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.03.2015

Inflammation in sleep apnea: An update

verfasst von: Dileep Unnikrishnan, Jonathan Jun, Vsevolod Polotsky

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Obstructive sleep apnea (OSA) is a common disorder associated with cardiovascular disease (CVD). One theory to explain this relationship proposes that OSA can induce systemic inflammation, thereby inducing CVD. This theory is based on the premise that obesity is a pro-inflammatory state, and that physiological derangements during sleep in subjects with OSA further aggravate inflammation. In support of this theory, some clinical studies have shown elevated inflammatory biomarkers in OSA subjects, or improvement in these markers following treatment of OSA. However, the data are inconsistent and often confounded by the effects of comorbid obesity. Animal models of OSA have been developed, which involve exposure of rodents or cells to intermittent hypoxia, a hallmark feature of OSA. Several of these experiments demonstrate that intermittent hypoxia can stimulate inflammatory pathways and lead to cardiovascular or metabolic pathology. In this review, we review relationships between OSA and inflammation, with particular attention to studies published within the last year.

Gastaut H, Tassinari CA, Duron B. Polygraphic study of the episodic diurnal and nocturnal (hypnic and respiratory) manifestations of the Pickwick syndrome. Brain Res. 1966;1(2):167–86.PubMed

Young T et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230–5.PubMed

Peppard PE et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015–21.PubMed

Berry RB et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the american academy of sleep medicine. J Clin Sleep Med. 2012;8(5):597–619.PubMedCentralPubMed

Somers VK et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96(4):1897–904.PubMedCentralPubMed

Dempsey JA et al. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47–112.PubMedCentralPubMed

Dempsey JA, Forster HV. Mediation of ventilatory adaptations. Physiol Rev. 1982;62(1):262–346.PubMed

Smith PL et al. Weight loss in mildly to moderately obese patients with obstructive sleep apnea. Ann Intern Med. 1985;103(6(Pt 1):850–5.

Weaver TE. Adherence to positive airway pressure therapy. Curr Opin Pulm Med. 2006;12(6):409–13.PubMed

10.

Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173–8.PubMedCentralPubMed

11.

Ng A et al. Oral appliance therapy for obstructive sleep apnea. Treat Respir Med. 2005;4(6):409–22.PubMed

12.

Maurer JT. Surgical treatment of obstructive sleep apnea: standard and emerging techniques. Curr Opin Pulm Med. 2010;16(6):552–8.PubMed

13.

Strollo Jr PJ et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370(2):139–49.PubMed

14.

Mesarwi, O.A., et al., Metabolic dysfunction in obstructive sleep apnea: A critical examination of underlying mechanisms. Sleep Biol Rhythm, 2014: p. n/a-n/a.

15.

Cassel W et al. Risk of traffic accidents in patients with sleep-disordered breathing: reduction with nasal CPAP. Eur Respir J. 1996;9(12):2606–11.PubMed

16.

Montesi SB et al. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med. 2012;8(5):587–96.PubMedCentralPubMed

17.

Schein AS et al. Continuous positive airway pressure reduces blood pressure in patients with obstructive sleep apnea; a systematic review and meta-analysis with 1000 patients. J Hypertens. 2014;32(9):1762–73.PubMed

18.

Fava C et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest. 2014;145(4):762–71.PubMed

19.

Punjabi NM et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004;160(6):521–30.PubMed

20.

Babu AR et al. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med. 2005;165(4):447–52.PubMed

21.

Drager LF, Jun J, Polotsky VY. Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):161–5.PubMedCentralPubMed

22.

Punjabi NM et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132.PubMedCentralPubMed

23.

Young T et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31(8):1071–8.PubMedCentralPubMed

24.

Peker Y et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med. 2002;166(2):159–65.PubMed

25.

Hung J et al. Association of sleep apnoea with myocardial infarction in men. Lancet. 1990;336(8710):261–4.PubMed

26.

Dyken ME et al. Investigating the relationship between stroke and obstructive sleep apnea. Stroke. 1996;27(3):401–7.PubMed

27.

Latina JM, Estes 3rd NA, Garlitski AC. The relationship between obstructive sleep apnea and atrial fibrillation: a complex interplay. Pulm Med. 2013;2013:621736.PubMedCentralPubMed

28.

Marin JM et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046–53.PubMed

29.

Arnaud C et al. Obstructive sleep apnea, immuno-inflammation, and atherosclerosis. Semin Immunopathol. 2009;31(1):113–25.PubMedCentralPubMed

30.

Jun J, Polotsky VY. Metabolic consequences of sleep-disordered breathing. ILAR J. 2009;50(3):289–306.PubMed

31.

Lavie L. Oxidative stress–a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis. 2009;51(4):303–12.PubMed

32.

Lavie L. Intermittent hypoxia: the culprit of oxidative stress, vascular inflammation and dyslipidemia in obstructive sleep apnea. Expert Rev Respir Med. 2008;2(1):75–84.PubMed

33.

McNicholas WT. Obstructive sleep apnea and inflammation. Prog Cardiovasc Dis. 2009;51(5):392–9.PubMed

34.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMed

35.

Liuzzo G et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417–24.PubMed

36.

Biasucci LM et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99(16):2079–84.PubMed

37.

Koenig W et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation. 1999;99(2):237–42.PubMed

38.

Haverkate F et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet. 1997;349(9050):462–6.PubMed

39.

Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–9.PubMed

40.

Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19(8):521–4.PubMed

41.

Vasse M et al. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis. 1996;26 Suppl 4:331–9.PubMed

42.

Wilhelmsen L et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311(8):501–5.PubMed

43.

Gerner RR et al. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol. 2013;91(11):867–72.PubMed

44.

Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14(3):137–45.PubMed

45.

Yudkin JS et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004;53(7):852–7.PubMed

46.

Visser M et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5.PubMed

47.

Gottlieb DJ et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014;370(24):2276–85.PubMedCentralPubMed

48.

Chirinos JA et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med. 2014;370(24):2265–75.PubMedCentralPubMed

49.

Craig SE et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. Thorax. 2012;67(12):1090–6.PubMed

50.

Kohler M et al. CPAP improves endothelial function in patients with minimally symptomatic OSA: results from a subset study of the MOSAIC trial. Chest. 2013;144(3):896–902.PubMed

51.

Stradling, J.R., et al., Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA. Thorax, 2014.

52.

Unuvar Dogan F et al. Relationships between obstructive sleep apnea syndrome, continuous positive airway pressure treatment, and inflammatory cytokines. Sleep Disord. 2014;2014:518920.PubMedCentralPubMed

53.

Kritikou I et al. Sleep apnoea, sleepiness, inflammation and insulin resistance in middle-aged males and females. Eur Respir J. 2014;43(1):145–55.PubMed

54.

Shamsuzzaman AS et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105(21):2462–4.PubMed

55.

Cheng TO. Could elevated C-reactive protein in patients with obstructive sleep apnea be due to obesity per se? Circulation. 2003;107(1):e9. author reply e9.PubMed

56.

Yokoe T et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107(8):1129–34.PubMed

57.

Kohler M et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax. 2009;64(1):67–73.PubMed

58.

Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep. 2004;27(8):1507–11.PubMed

59.

Barcelo A et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med. 2004;117(2):118–21.PubMed

60.

Ryan S et al. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax. 2007;62(6):509–14.PubMedCentralPubMed

61.

Sahlman J et al. The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea. J Sleep Res. 2010;19(2):341–8.PubMed

62.

Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2006;174(7):824–30.PubMed

63.

Gozal D et al. C-reactive protein and obstructive sleep apnea syndrome in children. Front Biosci (Elite Ed). 2012;4:2410–22.

64.

Kheirandish-Gozal L et al. Plasma C-reactive protein in nonobese children with obstructive sleep apnea before and after adenotonsillectomy. J Clin Sleep Med. 2006;2(3):301–4.PubMedCentralPubMed

65.

Ciccone MM et al. Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in obstructive sleep apnea. Molecules. 2014;19(2):1651–62.PubMed

66.

Bottazzi B et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157–83.PubMed

67.

Yasunaga T et al. Plasma pentraxin 3 is a more potent predictor of endothelial dysfunction than high-sensitive C-reactive protein. Int Heart J. 2014;55(2):160–4.PubMed

68.

Kobukai, Y., et al., Morning Pentraxin3 levels reflect obstructive sleep apnea-related acute inflammation. J Appl Physiol (1985), 2014.

69.

Oh IS et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709–12.

70.

Ramanjaneya M et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010;151(7):3169–80.PubMed

71.

Leivo-Korpela S et al. Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease. Mediat Inflamm. 2014;2014:232167.

72.

Tang CH et al. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012;36(1):39–45.PubMed

73.

Shen, P., et al., Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath, 2014.

74.

Emerging Risk Factors, C et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.

75.

Fibrinogen Studies C et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007;166(8):867–79.

76.

Shamsuzzaman, A., et al., Severity of obstructive sleep apnea is associated with elevated plasma fibrinogen in otherwise healthy patients. Sleep Breath, 2014.

77.

Basoglu OK et al. Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome. Ann Thorac Med. 2011;6(3):120–5.PubMedCentralPubMed

78.

Chin K et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1972–6.PubMed

79.

Kaditis AG et al. Morning levels of fibrinogen in children with sleep-disordered breathing. Eur Respir J. 2004;24(5):790–7.PubMed

80.

Phillips CL et al. Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study. Thorax. 2012;67(7):639–44.PubMed

81.

Guardiola JJ et al. Hypercoagulability in patients with obstructive sleep apnea. Sleep Med. 2001;2(6):517–23.PubMed

82.

Nizankowska-Jedrzejczyk A et al. Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial. J Clin Sleep Med. 2014;10(3):255–62.PubMedCentralPubMed

83.

Nojgaard C et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis. 2008;19(4):257–63.PubMed

84.

Nielsen AR et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes. 2008;57(11):3078–82.PubMedCentralPubMed

85.

Kazakova M et al. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int. 2013;33(2):341–6.PubMed

86.

Letuve S et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol. 2008;181(7):5167–73.PubMed

87.

Wang X, Xing GH. Serum YKL-40 concentrations are elevated and correlated with disease severity in patients with obstructive sleep apnea syndrome. Scand J Clin Lab Invest. 2014;74(1):74–8.PubMed

88.

Li W, Yu Z, Jiang C. Association of serum YKL-40 with the presence and severity of obstructive sleep apnea syndrome. Lab Med. 2014;45(3):220–5.PubMed

89.

Oh DY et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–98.PubMedCentralPubMed

90.

Ichimura A et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012;483(7389):350–4.PubMed

91.

Gozal D et al. Obstructive sleep apnea and obesity are associated with reduced GPR 120 plasma levels in children. Sleep. 2014;37(5):935–41.PubMedCentralPubMed

92.

Dovizio M et al. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol. 2014;114(1):118–27.PubMed

93.

Jun J et al. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2010;209(2):381–6.PubMedCentralPubMed

94.

Gautier-Veyret E et al. Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. Eur Respir J. 2013;42(2):404–13.PubMed

95.

Beaudin AE et al. Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea. J Am Heart Assoc. 2014;3(3):e000875.PubMedCentralPubMed

96.

Akkaya, E., M. Gul, and M. Ugur, Platelet to lymphocyte ratio: A simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol, 2014.

97.

Thomson SP, McMahon LJ, Nugent CA. Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol. 1980;17(4):506–14.PubMed

98.

Nelson DH et al. Blood levels of 17-hydroxycorticosteroids following the administration of adrenal steroids and their relation to levels of circulating leukocytes. J Clin Invest. 1952;31(9):843–9.PubMedCentralPubMed

99.

Koseoglu, H.I., et al., Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis, 2014.

100.

Kassi E et al. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31.PubMed

101.

Kheirandish-Gozal L, Peris E, Gozal D. Vitamin D levels and obstructive sleep apnoea in children. Sleep Med. 2014;15(4):459–63.PubMed

102.

Drager LF, Jun JC, Polotsky VY. Metabolic consequences of intermittent hypoxia: relevance to obstructive sleep apnea. Best Pract Res Clin Endocrinol Metab. 2010;24(5):843–51.PubMedCentralPubMed

103.

Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Med Clin. 2007;2(2):263–77.PubMedCentralPubMed

104.

Jun, J.C., et al., Intermittent Hypoxia-Induced Glucose Intolerance is Abolished by Alpha-Adrenergic Blockade or Adrenal Medullectomy. Am J Physiol Endocrinol Metab, 2014: p. ajpendo 00373 2014.

105.

Regazzetti C et al. Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes. 2009;58(1):95–103.PubMedCentralPubMed

106.

Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008;100(2):227–35.PubMed

107.

Drager LF et al. Chronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4. Am J Respir Crit Care Med. 2013;188(2):240–8.PubMedCentralPubMed

108.

He Q et al. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am J Physiol Endocrinol Metab. 2011;300(5):E877–85.PubMedCentralPubMed

109.

Lee YS et al. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell. 2014;157(6):1339–52.PubMed

110.

Shin MK et al. The effect of adrenal medullectomy on metabolic responses to chronic intermittent hypoxia. Respir Physiol Neurobiol. 2014;203C:60–7.

111.

Poulain L et al. Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis. Eur Respir J. 2014;43(2):513–22.PubMed

112.

Barcelo A et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur Respir J. 2011;37(6):1418–23.PubMed

113.

Jun J et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Physiol Regul Integr Comp Physiol. 2008;295(4):R1274–81.PubMedCentralPubMed

114.

Kanagy NL. Vascular effects of intermittent hypoxia. ILAR J. 2009;50(3):282–8.PubMedCentralPubMed

115.

Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation. 2005;112(17):2660–7.PubMed

116.

Jun JC et al. Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. Sleep. 2011;34(9):1207–13.PubMedCentralPubMed

117.

Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb. 1993;13(5):629–36.PubMed

118.

Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14(3):281–7.PubMed

119.

Zhou S et al. Deletion of metallothionein exacerbates intermittent hypoxia-induced oxidative and inflammatory injury in aorta. Oxid Med Cell Longev. 2014;2014:141053.PubMedCentralPubMed

120.

Cai L et al. Metallothionein in radiation exposure: its induction and protective role. Toxicology. 1999;132(2–3):85–98.PubMed

121.

Badran M et al. Chronic intermittent hypoxia causes endothelial dysfunction in a mouse model of diet-induced obesity. Sleep Med. 2014;15(5):596–602.PubMed

122.

Kaur C et al. Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland. J Pineal Res. 2007;42(4):338–49.PubMed

123.

Hung MW et al. Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. J Pineal Res. 2013;55(3):247–56.PubMed

124.

Totoson P et al. Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Exp Biol Med (Maywood). 2013;238(2):223–32.

125.

Smith SM, Friedle SA, Watters JJ. Chronic intermittent hypoxia exerts CNS region-specific effects on rat microglial inflammatory and TLR4 gene expression. PLoS One. 2013;8(12):e81584.PubMedCentralPubMed

126.

Trotta T et al. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol. 2014;268(1–2):1–12.PubMed

127.

Gozal E et al. Proteomic analysis of CA1 and CA3 regions of rat hippocampus and differential susceptibility to intermittent hypoxia. J Neurochem. 2002;83(2):331–45.PubMed

128.

Guven SF et al. The prevalence of obstructive sleep apnea in patients with difficult-to-treat asthma. Asian Pac J Allergy Immunol. 2014;32(2):153–9.PubMed

129.

Lu, Y., et al., [Treatment of obstructive sleep apnea-hypopnea syndrome for children refractory asthma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2014. 49(6): p. 462–7.

130.

Reinke C et al. Chronic intermittent hypoxia induces lung growth in adult mice. Am J Physiol Lung Cell Mol Physiol. 2011;300(2):L266–73.PubMedCentralPubMed

131.

Philippe, C., et al., Airway cell involvement in intermittent hypoxia-induced airway inflammation. Sleep Breath, 2014.

132.

Dancey DR et al. Impact of menopause on the prevalence and severity of sleep apnea. Chest. 2001;120(1):151–5.PubMed

133.

Bixler EO et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001;163(3 Pt 1):608–13.PubMed

134.

Gottlieb DJ et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352–60.PubMedCentralPubMed

135.

Campos-Rodriguez F et al. Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med. 2013;187(1):99–105.PubMed

136.

Torres M et al. Effect of ovariectomy on inflammation induced by intermittent hypoxia in a mouse model of sleep apnea. Respir Physiol Neurobiol. 2014;202:71–4.PubMed

137.

Somers VK, Abboud FM. Chemoreflexes–responses, interactions and implications for sleep apnea. Sleep. 1993;16(8 Suppl):S30–3.PubMed

138.

Somers VK et al. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol (1985). 1989;67(5):2101–6.

139.

Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest. 2010;137(1):95–101.PubMedCentralPubMed

140.

Deibert DC, Defronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest. 1980;65(3):717–21.PubMedCentralPubMed

141.

Halberg N et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol. 2009;29(16):4467–83.PubMedCentralPubMed

142.

Chinen I et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007;148(1):160–5.PubMed

143.

Imrie H, Abbas A, Kearney M. Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta. 2010;1801(3):320–6.PubMed

144.

Chouchou F et al. Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOF-SYNAPSE study. Eur Heart J. 2013;34(28):2122–31. 2131a.PubMed

Titel: Inflammation in sleep apnea: An update
verfasst von: Dileep Unnikrishnan
Jonathan Jun
Vsevolod Polotsky
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 1/2015
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-014-9304-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity

The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome

Angiogenesis in diabetes and obesity

Regulation of energy balance by inflammation: Common theme in physiology and pathology

The update of anthocyanins on obesity and type 2 diabetes: Experimental evidence and clinical perspectives